BAK1 (BCL2-antagonist/killer 1) is a pro-apoptotic protein belonging to the BCL2 family that plays a critical role in executing mitochondrial apoptosis. In neurons, dysregulated BAK1 activity contributes to pathological cell death in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions. Unlike its homolog BAX, which translocates to mitochondria upon apoptotic signaling, BAK1 is constitutively mitochondrial, making it a key therapeutic target for preventing neuronal loss.
| BAK1 Protein |
|---|
| Protein Name | BAK1 |
| Gene | [BAK1](/genes/bak1) |
| UniProt ID | [Q9Y2D5](https://www.uniprot.org/uniprot/Q9Y2D5) |
| PDB ID | 1JBQ, 2IMT, 4U2V |
| Molecular Weight | 23 kDa |
| Subcellular Localization | Mitochondria (constitutively) |
| Protein Family | BCL2 family (BAX/BAK subgroup) |
| Aliases | BAK, BCL2-KILLER |
BAK1 is a 23 kDa protein containing three functional domains:
- BH3 Domain: Critical for interaction with anti-apoptotic proteins (BCL2, BCL-XL, MCL1) and for activation by BH3-only proteins
- BH1 Domain: Required for oligomerization and pore formation
- BH2 Domain: Contributes to interaction with anti-apoptotic proteins
The protein adopts a canonical BCL2-family fold with alpha-helices surrounding a central hydrophobic core. In its inactive conformation, the BH3 domain is sequestered, preventing premature activation.
BAK1 is a key executor of mitochondrial apoptosis:
- Activation: Upon receipt of apoptotic signals, BH3-only proteins (BIM, BID, PUMA, NOXA) bind to and neutralize anti-apoptotic BCL2 proteins, liberating BAK1 (and BAX)
- Conformational Change: Activated BAK1 undergoes a dramatic conformational rearrangement, exposing its BH3 domain and oligomerization surfaces
- Oligomerization: BAK1 molecules assemble into homooligomers (typically 3-5 subunits) in the mitochondrial outer membrane
- Pore Formation: These oligomers create large pores (10-25 nm diameter) that facilitate mitochondrial outer membrane permeabilization (MOMP)
- Cytochrome c Release: MOMP releases cytochrome c and other pro-apoptotic factors into the cytosol, triggering the caspase cascade
Unlike BAX, which shuttles between cytosol and mitochondria, BAK1 is constitutively anchored to the mitochondrial outer membrane, allowing rapid response to apoptotic signals.
Cells require at least one functional executor (BAX or BAK1) for efficient apoptosis. Knockout of either alone provides partial resistance, but double knockout confers complete resistance to intrinsic apoptosis, demonstrating functional redundancy.
In AD, BAK1-mediated apoptosis contributes to neuronal loss through multiple mechanisms:
- Amyloid-β Toxicity: Amyloid-beta oligomers induce BAK1 activation and oligomerization in neurons [1]
- Tau Pathology: Hyperphosphorylated tau disrupts anti-apoptotic BCL2 proteins, sensitizing neurons to BAK1-dependent apoptosis [2]
- Mitochondrial Dysfunction: Aβ-induced mitochondrial dysfunction lowers the threshold for BAK1 activation
In PD, BAK1 plays a role in dopaminergic neuron degeneration:
- α-Synuclein Toxicity: Alpha-synuclein aggregation induces mitochondrial permeability transition and BAK1 activation [3]
- Mitochondrial Complex I Deficiency: Environmental toxins (MPTP, rotenone) that inhibit Complex I promote BAK1 oligomerization
- PINK1/Parkin Pathway: Dysfunction in mitophagy regulators correlates with increased BAK1 activity
| Condition |
Role of BAK1 |
| Amyotrophic Lateral Sclerosis |
Motor neuron death via excitotoxicity and oxidative stress |
| Huntington's Disease |
Mutant huntingtin sensitizes mitochondria to BAK1-mediated apoptosis |
| Stroke/Ischemia |
Ischemic injury activates BAK1-dependent neuronal death |
| Multiple Sclerosis |
Oligodendrocyte loss involves BAK1 execution |
Inhibiting BAK1 could prevent pathological neuronal death while potentially preserving normal apoptotic pathways in other tissues. However, complete inhibition may increase cancer risk.
- BH3 Mimetics: Small molecules that mimic BH3 domains can either activate or inhibit BAK1
- Direct Inhibitors: Specific BAK1 inhibitors are under development
- Indirect Inhibition: Targeting upstream regulators (BH3-only proteins, anti-apoptotic BCL2 proteins)
- Selectivity: Ideal inhibitors should spare BAX to maintain some apoptotic capacity
- CNS Penetration: Therapeutic agents must cross the blood-brain barrier
- Temporal Window: BAK1 inhibition may be most effective in early disease stages
- BAX: Can form heterooligomers with BAK1
- BIM: Potent activator of BAK1
- BID: Cleaved tBID directly activates BAK1
- PUMA: Strong activator, regulated by p53
- BCL2: Primary inhibitor of BAK1
- BCL-XL: Inhibits BAK1 oligomerization
- MCL1: Short half-life, dynamic regulation
- BCL2A1: Tissue-specific inhibitor
- Kiefer MC, et al. (1995). Targeted substitution of BAK1. Nature 374: 566-570
- Wei MC, et al. (2001). Proapoptotic BAK is activated. Cell 103: 645-656
- Lindsten T, et al. (2000). The combined functions of proapoptotic BAX and BAK are essential for development. Mol Cell 6: 1389-1399
- Kiefer MC, et al. (1995). Targeted substitution of BAK1 reveals essential role of BH3-only proteins. Nature 374: 566-570.
- Wei MC, et al. (2001). Proapoptotic BAK is activated by BH3-only proteins. Cell 103: 645-656.
- Lindsten T, et al. (2000). The combined functions of proapoptotic BAX and BAK are essential for development. Mol Cell 6: 1389-1399.